RxDoctor Payments Data

Siyun Li, MD

Neurology · Chillicothe, OHNPI 1902821366

Payments from drug & device makers

$4,185in general payments, 2019–2025

Across 277 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$849
  • Neurocrine Biosciences, Inc.$768
  • Amneal Pharmaceuticals LLC$465
  • SK Life Science, Inc.$304
  • Lilly USA, LLC$244
  • Bristol Myers Squibb$212
  • plus $1K from 22 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$4,14999%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,185 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$76,060
Medicare patients
420
Services billed
1,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate29$221,933
VumerityDiroximel Fumarate11$94,023
Nurtec OdtRimegepant Sulfate63$89,308
Aimovig AutoinjectorErenumab-Aooe70$52,616
RytaryCarbidopa/Levodopa31$46,909
UbrelvyUbrogepant26$27,954
GlatopaGlatiramer Acetate15$24,060
Emgality PenGalcanezumab-Gnlm30$22,394
XcopriCenobamate55$16,817
FycompaPerampanel12$14,108
Ajovy AutoinjectorFremanezumab-Vfrm14$10,620
SunosiSolriamfetol Hcl11$9,581
Sumatriptan Succinate144$9,469
Levetiracetam306$6,929
Oxcarbazepine118$5,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$768$221,93329 claims
BiogenVumerity$169$94,02311 claims
PfizerNurtec Odt$69$89,30863 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$465$49,05071 claims
AbbVieUbrelvy$849$27,95426 claims
SK Life Science, Inc.Xcopri$304$16,81755 claims
Eisai Inc.Fycompa$128$14,10812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 702 neurology providers in Ohio.

Other neurology in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →